e-PPGC 2017 - Day 1
3/16/2017 6:30 AM to 3/16/2017 3:00 PM
3/18/2019 12:59 PM
Password or Payment Required
|8:00am-8:10am||Welcome and Opening Remarks|
|TRACK/THEME||CARE OF THE NEONATE AND INFANT|
Moderator: Phil Newcomm, MD
S101- HEALTHY BEGINNINGS: Infant Feeding & Optimal Nutrition of the Newborn Infant
This session will cover all aspects of infant feedings in the healthy newborns including: Adequate amount, type of formulas, avoiding overfeeding, transitioning from breast milk to formula, timing of introduction to solids, etc.
S102- NEONATAL HYPOGLYCEMIA: What’s New?
This session will cover on neonatal hypoglycemia. While hypoglycemia is common among neonates, treatment can be challenging if hypoglycemia persists beyond the first few days of life. This session discusses treatment options for both transient and persistent neonatal hypoglycemia. These treatment options include dextrose infusions, glucagon, glucocorticoids, diazoxide, octreotide, and nifedipine. A stepwise, practical approach to the management of these patients is will be discussed.
S103- NEONATAL JAUNDICE: The Good, The Bad, and The Worrisome
This session will discuss neonatal jaundice and its differential diagnosis from benign transient physiologic jaundice to the worrisome pathologic jaundice. This session will be based on the AAP guidelines and will focus on the role of the primary care provider in the identification and work-up.
|TRACK/THEME||COMMON ISSUES IN PRIMARY CARE|
S104- RECOGNIZING PEDIATRIC MALNUTRITION: No Longer Failure to Thrive
This session will focus on the identification standards for pediatric malnutrition (under nutrition) endorsement by the AAP. The recommendation of use of z scores vs percentiles on growth charts will be discussed and practical application of the standards for the PMD will be reviewed.
|Moderator: Marisa Azaret, PsyD|
S105, S106- FIRST DO NO HARM: (Panel)- Unintended Consequences of Common Treatments
Luis Mendoza, MD
This session is framed as a panel discussion. It is slated for 60 minutes with 5 speakers 10 minutes each leaving 10 minutes for Q&A. The speakers would focus on common practices/ treatment strategies/ approaches which has emerging evidence of unintended immediate or future harm to the patient. The speakers should highlight the emerging evidence as parents might be coming to the pediatrician with questions. This will provide the pediatrician with ways to address these questions.
Moderator: Nolan Altman, MD
This session will cover the normal marrow transformation and the diagnostic imaging modalities for marrow disorders and the types of marrow disorders the MRI findings.
Faculty, Moderators, and Planners’ Disclosures
None of the PPGC speakers, moderators, and scientific planning committee members (and their spouse/partner) had any COIs or financial relationships to disclose in the past 12 months or plan to discuss unlabeled or investigational use of a drug, device, or product not approved in the U.S. except for the one(s) listed below:
|Faculty, Moderator or Planner||Person with COI or financial relationship||Company||Role/Relationship||Discussion of Investigational/Unlabeled Drugs or Devices|
|Ibrahim Amjad, MD||Self||None||None||Mixing of Enteral Formula|
|Richard Arboleda, MD, MPH||Self||Otsuka||Consulting Fee||None|
|Diva De Leon-Crutchlow, MD||Self||Xoma Corporation||Contracted Research|
18FDOPA PET SCAN for identification of focal hyperinsulinism lesions (Investigational use)
|Self||Biomarin Pharmaceuticals||Contracted Research|
|Self & Spouse/Partner||Merck||Ownership Interest|
|Kelly Green Corkins, MS, RD, LDN, CNSD||Self||Nestle Nutrition||Consulting Fee||None|
|Vivian Hernandez-Trujillo, MD||Self||Meda||Honoraria||None|
|Self||Bayer||Honoraria & Consulting Fee, Claritin Council Member|
All COIs have been resolved prior to the meeting. Faculty will disclose financial relationships or COIs to the audience verbally and/or with a slide at the beginning of their presentation.